New Potential Drug to Treat advanced Melanomaby
Medical QuackClinicalTrials state that the drug is prolonging life and also showing to shrink tumors. We may all remember... there’s the Danny Fund foundation where you can contribute. This study looks good, but a larger clinicaltrial will be started
Tysabri and Melanoma - Company Rebuttal Disputes Linkby
Joan ..
cause and effect. The authors reviewed safety data from several clinicaltrials of Tysabri involving thousands... Tysabri and melanoma -- it appears that there may not be a causal connection between the two after all. I'm
Huperzine A in Alzheimer's Disease-The ClinicalTrialby
Bob DeMarco
The Huperzine A in Alzheimer's Disease clinicaltrial is currently open and recruiting patients. This is a Phase II clinicaltrial.
Also see Huperzine A Factsheet
Huperzine A in Alzheimer's Disease-The ClinicalTrial
Facts About Melanomaby
Healthy-Clues ..
•Melanoma increased 690% in the U.S. from 1950 to 2001. •There will be about 60,000 cases of melanoma this year. •There will be about 8,000 melanoma deaths this year. •Every 65 minutes, one person dies of melanoma
Melanoma- Health Encyclopedia and Reference Melanoma Symptoms, Treatments and Medications ... and many scientists are conducting basic research and clinicaltrials to find better forms of treatment. ...
Melanoma These patients also should consider participating in clinicaltrials. ... For melanoma that has spread to other tissues and organs, the cure rate is low. ...
Melanoma - Symptoms, Treatment and Prevention Up-to-the-minute news coverage of national, regional and international news enhanced with audio and video clips and photo galleries - updated 24/7...
Melanoma and Other Skin Cancers - Treatment for Melanoma A phase II trial in patients with Stage IV melanoma showed tumor disappearance ... A 2004 randomized clinicaltrial showed that neither interferon alpha-2b nor interferon ...
Melanoma These patients also should consider participating in clinicaltrials. ... Note: All clinical content on this site is physician-reviewed, except material generated ...
Melanoma and Other Skin Cancers - Diagnosis Melanoma and Other Skin Cancers - Diagnosis ... survival, no clinicaltrials have proven to date that this procedure improves the prognosis in melanoma. ...
News
Phase 2 Data On Provectus's PV-10 To Be Presented At The 2010 ASCO Scientific Program On June 4 - 8 In Chicago Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 - 8, 2010 in Chicago, Illinois. Dr. Sanjiv Agarwala, Chief, Medical ...
PETER HARMAN GOODENOW Peter Harman Goodenow, son of Robert and Jacqueline Goodenow, died Jan. 8, 2010, at Gilchrist Hospice in Townson, Md., after a long battle with melanoma.
New Drug Gives Hope To Melanoma Patients A new treatment for melanoma being tested in Chicago could do more than kill the deadliest form of skin cancer, it could prevent it from ever coming back. CBS 2's Suzanne Le Mignot reports.
Press Release Provectus Pharmaceuticals Inc. Posted on:19 Mar 10 Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in ...
Cancer genes silenced in humans Tiny particles carrying short strands of RNA can interfere with protein production in tumours.
Going Bald for a Cause Amy Henry, the first woman to shave her head at the 2010 st. baldrick's fundraiser, does so with a stranger and family in mind.
Roche to Introduce at Least Six New Medicines By 2015 (Update2) March 18 (Bloomberg) -- Roche Holding AG plans to strengthen its position in oncology and expand in therapeutic areas such as metabolism and inflammation, introducing at least six new medicines by 2015.
Abraxis Reports Good NSCLC Results; Pancreatic Data Pending Abraxane combined with carboplatin was shown to be superior to Taxol plus carboplatin in terms of overall response rate in a Phase III study in patients with non-small-cell lung cancer (NSCLC), Abraxis BioScience Inc. reported.
Molecular Insight Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial and Operational Results CAMBRIDGE, MA--(Marketwire - March 16, 2010) - Molecular Insight Pharmaceuticals, Inc. ( NASDAQ : MIPI ), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced financial and operational results for the fourth quarter and year-ended December 31, 2009.
Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted ...